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Original Research
Early-Stage Development of Novel Cyclodextrin-siRNA
Nanocomplexes Allows for Successful Postnebulization
Transfection of Bronchial Epithelial Cells
A. Hibbitts, PhD,1 A. O’Mahony, PhD,2 E. Forde, MPharm,1 L. Nolan, MPharm,1 J. Ogier, PhD,3
S. Desgranges, PhD,3 R. Darcy, PhD,3 R. MacLoughlin, PhD,4 C. O’Driscoll, PhD,2 and S.A. Cryan, PhD1,5
Abstract
Background: Successful delivery of small interfering RNA (siRNA) to the lungs remains hampered by poor
intracellular delivery, vector-mediated cytotoxicity, and an inability to withstand nebulization. Recently, a
novel, cyclodextrin (CD), SC12CDClickpropylamine, consisting of distinct lipophilic and cationic subunits, has
been shown to transfect a number of cell types. However, the suitability of this vector for pulmonary siRNA
delivery has not been assessed to date. To address this, a series of high-content analysis (HCA) and post-
nebulization assays were devised to determine the potential for CD-siRNA delivery to the lungs.
Methods: SC12CDClickpropylamine-siRNA mass ratios (MRs) were examined for size and zeta potential. In-
depth analysis of nanocomplex uptake and toxicity in Calu-3 bronchial epithelial cells was examined using IN
Cell HCA assays. Nebulized SC12CDClickpropylamine nanocomplexes were assessed for volumetric median
diameter (VMD) and fine particle fraction (FPF) and compared with saline controls. Finally, postnebulization
stability was determined by comparing luciferase knockdown elicited by SC12CDClickpropylamine nano-
complexes before and after nebulization.
Results: SC12CDClickpropylamine-siRNA complexation formed cationic nanocomplexes of £ 200 nm in size
and led to significantly higher levels of siRNA uptake into Calu-3 cells compared with RNAiFect-siRNA–
treated cells at all MRs ( p< 0.001, n¼3· 4), with evidence of toxicity only at MRs 50–100. Nebulization
of SC12CDClickpropylamine nanocomplexes using the Aeroneb Pro resulted in VMDs of *5lm and FPFs
of *57% at all MRs. SC12CDClickpropylamine-siRNA–mediated luciferase knockdown was found to be
39.8– 3.6% at MR¼20 before and 35.6– 4.55% after nebulization, comparable to results observed using
unnebulized commercial transfection reagent, RNAiFect.
Conclusions: SC12CDClickpropylamine nanocomplexes can be effectively nebulized for pulmonary delivery
of siRNA using Aeroneb technology to mediate knockdown in airway cells. To the best of our knowledge, this
is the first study examining the suitability of SC12CDClickpropylamine-siRNA nanocomplexes for pulmonary
delivery. Furthermore, this work provides an integrated nanomedicine–device combination for future in vitro
and in vivo preclinical and clinical studies of inhaled siRNA therapeutics.
Key words: vibrating mesh nebulizer, RNAi, nonviral gene delivery, high-throughput screening, Calu-3 cells
Introduction
Local delivery of small interfering RNA (siRNA) tothe lungs represents a promising means of treating a
range of pulmonary conditions such as asthma, influenza, and
lung cancer.(1–4) However, progression from the preclinical
to the clinical setting remains hampered by a range of host
defense mechanisms and pharmaceutical delivery issues.
These include rapid clearance via the mucociliary escalator,
entrapment and degradation by alveolar macrophages, and
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activation of the innate immune systems via toll-like re-
ceptors.(5–7) Coupled with this, pharmaceutical issues that
are currently impeding pulmonary siRNA therapy include
nanoparticle-induced toxicity, inefficient rates of siRNA
nanoparticle delivery, and low levels of postdelivery siRNA
stability (reviewed previously(8–10)). With these obstacles in
mind, it is extremely important to confront both of these
areas in order to successfully develop pulmonary siRNA
therapy.
Following the selection of an appropriate platform for
delivery, it is also necessary to design an siRNA delivery
vector capable of withstanding the nebulization process
and successfully transfecting airway cells. The use of cat-
ionic polymers for nucleic acid delivery has been well
established as an efficient means of nonviral gene deliv-
ery. However, although synthetic polymers such as poly-
ethylenimine (PEI) have demonstrated high levels of gene
knockdown, they have been widely reported to be cytotoxic
and immunogenic.(11–15) Following from these studies,
current efforts are now turning toward alternative carrier
molecules to improve toxicity while maintaining transfec-
tion efficiency.
Recently, we have developed a novel amphiphilic b-
cyclodextrin (b-CD) that has been modified via ‘‘click’’
chemistry to possess cationic moieties (F1c Fig. 1), rendering
it a potential siRNA delivery vector. Studies to date
have found it to be effective at delivering siRNA to both
gastrointestinal–epithelial and neuronal cells(16,17); how-
ever, its potential for pulmonary delivery of siRNA has not
yet been assessed. To date, research into CD delivery to the
lungs has focused primarily on enhancing solubility of
preexisting small-molecule drugs,(18,19) mitigating their cy-
totoxic effects,(20) and improving the respirable fraction and
absorption of aerosolized drugs.(21–23) CDs have also been
adapted for gene delivery using a multitude of different CD
conformations, including functionalization of CD–OH ter-
minals with cell-targeting ligands and poly(ethyleneglycol)
moieties, cell-penetrating peptides, cationic dendrimers, and
CD block copolymers (comprehensively reviewed previ-
ously(24–27)). To date, none of these CDs have been used for
transfection of airway epithelial cells.
In this study, we apply a range of high-throughput, mul-
tiparameter screening methods to obtain both qualitative and
quantitative data regarding siRNA uptake efficiency and
cytotoxicity in Calu-3 bronchial epithelial cells over a range
of doses and time points. In addition, we investigate the
ability of novel SC12CDClickpropylamine siRNA nano-
complexes to effect in vitro gene knockdown both before




All cell culture and high-content analysis (HCA) reagents
were obtained from Invitrogen Corporation (Carlsbad, CA),
unless otherwise stated. The Calu-3 bronchial epithelial cell
line was obtained from the American Tissue Type Culture
Collection (ATCC, Manassas, VA) and used at passages 20–
50. siGENOME Non-Targeting siRNA #2 (5¢ UAAGG
CUAUGAAGAGAUAC 3¢) was obtained from Dharmacon
(Lafayette, CO). The non-targeting sequence #2 is nonspe-
cific for human gene sequences and specific for firefly lu-
ciferase using the Promega pGL3 cloning vector. AllStars
negative control siRNA was obtained from Qiagen UK
(Manchester, UK). This siRNA has no homology to any
known mammalian gene and has been validated using
Affymetrix GeneChip arrays and a variety of cell-based
assays. AllStars negative control siRNA was also obtained
from Qiagen with a fluorocein isothiocyanate (FITC)
modification for cell uptake studies. The modified CD
SC12CDClickpropylamine (Fig. 1) was produced in-house
as previously described.(16) Aeroneb Pro vibrating mesh
nebulizers were a kind gift from Aerogen Ltd. (Galway,
Ireland). All other general chemicals and reagents used
were of the highest grade possible and were obtained from
Sigma-Aldrich Company Ltd. (Dorset, UK), unless other-
wise stated.
FIG. 1. Chemical structure of novel click-modified cat-
ionic CD.(39)
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Formation of SC12CDClickpropylamine-siRNA
nanocomplexes
CD nanocomplexes were formed using a film evaporation
method whereby CDs were first dissolved in chloroform at
1mg/mL in a round-bottomed flask. The solvent was then
evaporated using a rotary evaporator. Evaporated films were
stored at - 20C until required. For preparation of SC12CD
Clickpropylamine-siRNA complexes, SC12CDClickpropy-
lamine was rehydrated with deionized water at a final con-
centration of 1mg/mL and sonicated for 1 hr at room
temperature (RT). Resuspended SC12CDClickpropylamine
was then mixed at various mass ratios (MRs) with 20lM
siRNA (lg of CD/lg of siRNA) in an equal volume of
RNase-free water to a final volume of 1 lM siRNA and used
after 20–30min.
Size and zeta potential of SC12CDClickpropylamine-
siRNA nanocomplexes
SC12CDClickpropylamine nanocomplex particle size and
charge were measured with Malvern’s Zetasizer Nano ZS
instrument, using laser-light scattering and electrophoretic
mobility measurements, respectively. CD-siRNA (3 lg of
siRNA) nanocomplexes were prepared by the ‘‘mixing
method.’’ The resulting mixtures were made up to 1mL
with 0.2-lm filtered deionized water (dH2O) or phosphate-
buffered saline (PBS) at pH 7.4. Five readings of Z-average
size (nm), polydispersity (25C, measurement angle 170),
and zeta potential (mV; 25C, measurement angle 12.8)
were taken. For data analysis, the viscosity (0.8872
mPa$sec) and refractive index (1.33) of water were used to
determine Z-average size. The data are presented as
means – standard error of the mean (SEM).
SC12CDClickpropylamine-siRNA nanocomplex
uptake in Calu-3 cells
Calu-3 cells were seeded at 3· 104 cells/well in a 96-well
plate (Nunc). Nanocomplexes were formed as described.
Cells in 125lL of serum-free Dulbecco’s modified Eagle’s
medium (DMEM) were treated with nanocomplexes con-
taining 100 nM fluorescently tagged FITC siRNA at 37C and
5% CO2 for 2, 4, and 24hr. Cells were washed with PBS and
fixed using 4% paraformaldehyde. Cells were stained using
phalloidin–tetramethylrhodamine isothiocyanate (TRITC)
and Hoechst nuclear stain. Image analysis was achieved using
the IN Cell 1000 High Content Analyzer (GE Healthcare,
Little Chalfont, Buckinghamshire, UK). Four random fields
were viewed per well, and the various MRs were repeated in
quadruplicate. Fluorescence intensity of the dyes was moni-
tored at the excitation and emission wavelengths specific to
each dye (i.e., 360 nm and 460 nm for Hoechst, 480 nm and
535 nm for FITC-siRNA, and 535 nm and 600 nm for phal-
loidin-TRITC). Exposure times were varied to optimize im-
age quality for each individual experiment. After acquisition
of the images, the data were analyzed using IN Cell 1000
Workstation software (GE Healthcare, UK) using multitarget
analysis with a variety of settings for each of the parameters
shown in bT1Table 1.
bAU2
Analysis was carried out on siRNA na-
nocomplexes found in the cytoplasm only, as this is the active
site for siRNA-mediated genetic knockdown. Any complexes
found outside the cell and in the nuclear area were auto-
matically ignored using the segmentation setting available in
the IN Cell 1000 Workstation software. All samples were run
in quadruplicate and the experiment repeated on three inde-
pendent occasions.
Multiparameter analysis of SC12CDClickpropylamine
nanocomplex toxicity in Calu-3 cells
Twenty-four hours prior to transfection, cells were seeded
3· 104/well in a 96-well plate. SC12CDClickpropylamine-
siRNA nanocomplexes were formed as previously described,
and cells were treated with nanocomplexes containing 100
nM siRNA for 24hr. Furthermore, selected wells were treated
with 120lM valinomycin or 40lM carbobenzoxy-L-leucyl-
L-leucyl-L-leucinal (MG132) for 24 hr as a positive control
prior to analysis. Following incubation, cells were stained and
fixed using the Cellomics Multiparameter Cytotoxicity 3 kit
(Thermo Scientific, Waltham, MA) according to its protocol.
In brief, cells were live-stained for mitochondrial membrane
potential (MMP) and plasma membrane permeability (PMP).
Cells were then fixed using 4% paraformaldehyde before
staining with Hoechst nuclear stain and fluorescent antibody
labeling for cytochrome c. Image acquisition was determined
using the IN Cell 1000 High Content Analyzer.
Four random fields were viewed per well, and the various
MRs were repeated in quadruplicate. Fluorescence intensity
of the dyes was monitored at the excitation and emission
wavelengths specific to each dye (i.e., 360 nm and 460 nm
for Hoechst, 480 nm and 535 nm for the permeability dye,
535 nm and 600 nm for MMP dye, and 646/674 nm for
DyLight 649 conjugates). Exposure times were varied be-
tween experiments to optimize image quality for each in-
dividual experiment. Following acquisition of the images,
the data were analyzed using IN Cell 1000 Workstation
software (GE Healthcare, UK) using multitarget analysis
with a variety of settings for each of the parameters ( bT2Table 2).
All samples were run in quadruplicate and the experiment
repeated on three independent occasions.
Nebulizer droplet size characterization
by laser diffraction
Droplet size distributions described by volumetric median
diameter (VMD) were measured by a Malvern Spraytec
Table 1. Settings for IN Cell 1000 Workstation Analysis of RNAiFect/SC12CDClickpropylamine-siRNA
Nanocomplex Uptake into Calu-3 Cells
Feature Source Segmentation Min. area Sensitivity Collar
Nuclei Wave 1 (Hoechst) Top hat 50 lm2 100% —
Cell Wave 2 (TRITC) Collar — — 7lm
Organelles Wave 3 (FITC) Cytoplasm only 0.05–0.5 lm2 50% —
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particle size analyzer for several different CD-siRNA na-
nocomplex MRs. (Malvern Instruments Ltd., Malvern,
Worcestershire, UK) with RT Sizer software (version 5.60).
A 5 L/min vacuum flow was implemented through the
system, ensuring laminar flow and reducing artificial droplet
size growth through collision with other droplets. The vac-
uum also ensured that the droplets passed through the laser
beam only once. The center of the emitted aerosol plume
was directed through the center of the laser beam to increase
the accuracy of data acquisition.
Data acquisition began when beam obscuration exceeded
3% and continued until the end of dosing. The data acqui-
sition rate was set to 500Hz, that is, 500 individual readings
per second were taken characterizing the droplet size dis-
tribution. The value reported for each individual measure-
ment is an average of the individual readings recorded over
the course of the dose. In order to verify the accuracy of the
generated data, the Spraytec analyzer’s laser diffraction
apparatus was tested with a reference reticle (Malvern In-
struments Ltd.). Droplet size is described by VMD (Dv50).
The fine particle fraction (FPF; percentage of droplets less
than 5 lm in size) was also recorded.
Luciferase knockdown in Calu-3 cells using pre-
and postnebulization using SC12CDClickpropylamine-
siRNA nanocomplexes
Calu-3 cells were seeded at a density of 5 · 104 in 48-well
plates 24 hr prior to transfection. Following this, cells were
first transfected with luciferase pGL3 control vector plasmid
(Promega, Southampton, UK) and SuperFect transfection
reagent (Qiagen, UK). Cells were transfected using 0.75 lg
of pDNA/3 lL of SuperFect in 100 lL of serum-free DMEM
per well for 4 hr. For unnebulized samples, siRNA nano-
complexes were formed in PBS following initial resuspen-
sion in dH2O using anti-luciferase siRNA or nontargeting
control siRNA as previously described and diluted to a final
concentration of 100 nM per well in serum-containing me-
dia. Positive controls of RNAiFectTM (Qiagen, UK) siRNA
nanocomplexes were formed according to the manufactur-
er’s instructions at an siRNA:RNAiFect MR of 1:9 and di-
luted in serum-containing media to a final concentration of
100 nM. Cells were then treated with 250lL of the final
sample and incubated for 24 hr at 37C and 5% CO2.
For postnebulization nanocomplexes, SC12CDClickpro-
pylamine-siRNA nanocomplexes were formed as previously
described, with the exception of using PBS instead of
serum-containing media, to a concentration of 500 nM.
Nanocomplex solutions were then nebulized through the
Aeroneb Pro (Aerogen) until no sample remained on the
medication feed side of the nebulizer. Postnebulization
samples were collected by nebulizing directly into a sealed
15-mL tube containing serum-containing media. Nebulized
samples were allowed to condense before being centrifuged
at 1,000 rpm for 3min and diluted to a final concentration of
100 nM using serum-containing media. Cells were then
treated with 250 lL of the collected sample and incubated
for 24 hr at 37C and 5% CO2. Following incubation, all
samples were analyzed for luciferase expression using the
luciferase assay system (Promega) and read using a Wallac
1420 Multilabel Counter (PerkinElmer, Waltham, MA).
Protein expression in each sample was examined using the
Micro BCA protein assay kit (Pierce) according to prod-
uct instructions. All samples were run in quadruplicate and
the experiment repeated on three independent occasions.
Statistical analysis
Results are expressed as means – SEM using GraphPad
Prism 5 software. Two- and one-way analysis of variance
(ANOVA) for differences between treatments with p< 0.05
considered significant, p< 0.01 very significant, and
p < 0.001 highly significant.
Results
Size and zeta potential of SC12CDClickpropylamine-
siRNA nanocomplexes
In order to determine the optimal MR for nanocomplex
formation in CD-siRNA nanocomplexes, a range of MRs
were examined for particle size and zeta potential. For the
SC12CDClickpropylamine-siRNA nanocomplexes prepared
in dH2O, MRs from 10 to 100 were examined. It was found
that SC12CDClickpropylamine nanocomplexes formed
compact structures under 200 nm in size at all MRs, with the
most compact nanocomplexes forming at MR= 20 and 30
( b F2Fig. 2A). Examination of corresponding polydispersity in-
dices (PDIs) for siRNA nanocomplexes measured indicated
that siRNA nanocomplexes were of a more monodisperse
nature at MRs 10–30, with higher levels of heterogeneity at
MR = 50 and MR = 100. However, overall, samples re-
mained relatively polydisperse. On analysis of the dH2O
SC12CDClickpropylamine nanocomplex’s corresponding
zeta potentials, it was found that at all MRs 10–100 the
nanocomplexes were highly cationic. Furthermore, cationic
charge increased with increasing MR. However, this in-
crease became less pronounced after the MR of 20 (Fig. 2B).
On analysis of the siRNA nanocomplexes formulated in
PBS, it was found that there was a very significant increase
in size across all MRs to the micrometer range with PDIs
Table 2. Settings for IN Cell 1000 Workstation Analysis of SC12CDClickpropylamine-siRNA
Nanocomplex–Induced Toxicity in Calu-3 Cells
Feature Source Segmentation Min. area Sensitivity Collar
Nuclei Wave 1 (NA, NI, CN) Top hat 50 lm2 100% —
Cell Wave 2 (PMP) Collar — — 8 lm
Reference 1 Wave 3 (Cyt c) Pseudo-cells — — —
Reference 2 Wave 4 (MMP) Pseudo-cells — — —
Reference 3 Wave 2 (PMP) Pseudo-nuclei — — —
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indicating a heterogeneous population. Examination of PBS
samples also demonstrated a significant decrease in charge.
However, the overall trend of increasing positive surface
charge with increasing MR remained evident (Fig. 2).
HCA analysis of SC12CDClickpropylamine-siRNA
nanocomplex uptake in Calu-3 cells
To adequately assess cell uptake of CD-siRNA nano-
complexes in Calu-3 cells over a wide range of MRs and
incubation times, high-throughput methods were developed
that allowed for both a visual qualitative and quantitative
examination. Cells were treated with FITC-tagged SC12CD
Clickpropylamine-siRNA nanocomplexes and incubated for
either 2, 4, or 24 hr at 37C in order to determine the optimal
MR for siRNA delivery using the different SC12CDClick-
propylamine MRs, as well as gaining an insight into the
rates at which the different nanocomplexes were internal-
ized into the cell.
Using the cell organelle segmentation parameters of the IN
Cell data acquisition software, it was possible to discriminate
individual siRNA nanocomplexes internalized within the
cell membrane to gain a quantitative understanding of na-
nocomplex uptake efficiency. It was found that SC12CD
Clickpropylamine-siRNA nanocomplexes were capable of
facilitating high levels of siRNA internalization into Calu-3
cells at all MRs studied (F3c Fig. 3). Levels of siRNA internal-
ization were significantly higher in SC12CDClickpropyla-
mine nanocomplex–treated cells over all MRs and incubation
times compared with RNAiFect. For example, at MR= 20,
uptake versus RNAiFect siRNA nanocomplexes at 2, 4, and
24 hr post treatment was 1,049 – 137 versus 494 – 79,
1,598– 153 versus 258 – 53, and 1,927– 94 versus 322– 103
internalized nanocomplexes per well, respectively.
It was also observed that SC12CDClickpropylamine na-
nocomplex composition appeared to affect its cellular par-
ticokinetics in terms of both the level and the rate of
internalization. For the SC12CDClickpropylamine-siRNA
nanocomplexes formed at higher MRs (MR‡ 30), it was
found that there were no significant differences in the levels
of internalization after 2, 4, and 24 hr of incubation. For
example, MR = 100 nanocomplex uptake was 1,565 – 145,
1,413– 158, and 1,516– 298 internalized nanocomplexes
per well after 2, 4, and 24 hr of incubation. In contrast, there
were significant changes in levels of internalized nano-
complexes at MR = 10 and MR= 20 at each different time
point.
It would appear that nanocomplexes formed at higher
MRs undergo rapid internalization and intracellular pro-
cessing, whereas low-MR SC12CDClickpropylamine na-
nocomplexes are internalized at a slower rate but ultimately
FIG. 2. (A) Particle size, PDI, and (B) zeta potential of
SC12CDClickpropylamine-siRNA nanocomplexes at MRs
10–100 using either dH2O or PBS (two-way ANOVA, n = 5,
means – SEM, ***p < 0.001).
FIG. 3. HCA 20 · fused image analysis of SC12CD
Clickpropylamine-siRNA nanocomplex uptake in Calu-3
cells 24 hr post transfection. Cells were treated with 100 nM
concentration of FITC-tagged siRNA nanocomplexes (green)
b 4C
and were subsequently stained for cell nuclei using Hoechst
nuclear stain (blue) and for cell membrane using phalloidin-
TRITC (red). (A) FITC-siRNA–treated cells. (B) CDMR=10.
(C) CD MR=20. (D) CD MR=30. (E) CD MR=50. (F) CD
MR= 100. (G) Quantitative HCA analysis of RNAiFect ver-
sus SC12CDClickpropylamine nanocomplex uptake in Calu-3
cells measured at 2, 4, and 24hr post administration (two-way
ANOVA, n= 3, means–SEM, ***p< 0.001).
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result in higher levels of nanocomplex internalization. Evi-
dence of this was found in the overall rate of internalization
for SC12CDClickpropylamine nanocomplexes. At 2 hr post
treatment, the highest level of internalization was seen in
SC12CDClickpropylamine nanocomplexes at MR= 100;
however, over the full 24 hr of treatment, the highest levels
of internalization were seen in SC12CDClickpropylamine
nanocomplexes at MR = 20. At 24 hr post transfection, levels
of internalized SC12CDClickpropylamine-siRNA nanocom-
plexes were significantly higher using an MR= 20 formula-
tion compared with RNAiFect and all other SC12CDClick
propylamine-siRNA nanocomplexes used. This demonstrated
that over 24 hr the optimal MR for intracellular delivery of
siRNA delivery novel cationic CDs was at MR= 20.
Multiparameter analysis of SC12CDClickpropylamine
nanocomplex toxicity in Calu-3 cells
Assessing the dose-toxicity relationship of novel trans-
fection materials is a crucial element in their clinical and
regulatory development. As with the nanocomplex uptake
studies described, high-throughput screening methods were
harnessed to carry out a multiparameter cytotoxicity study.
Calu-3 cells were incubated with 100 nM SC12CDClick-
propylamine-siRNA nanocomplexes per well over a range
of CD:siRNA MRs for 24 hr. Following this, cell viability
and nanocomplex-mediated toxicity were qualitatively and
quantitatively determined using the Cellomics Multi-
parameter Cytotoxicity 3 kit and IN Cell 1000 Workstation
software for analysis.
For these experiments, the positive toxic controls con-
sisted of the ionophore, valinomycin, and the proteasome
inhibitor MG132 (Z-Leu-Leu-Leu-Al). Valinomycin is a K +
ionophore that selectively transports K+ ions through the
cell membrane leading to mitochondrial swelling, cyto-
chrome c release, and autophagic processes.(28,29) In con-
trast, MG132 is a peptide aldehyde and is a potent inhibitor
of the 26S proteasome complex that effectively blocks its
proteolytic activity via the chymotrypsin degradation path-
way.(30) Doses as low as 1–30 lM (compared with 120lM
for valinomycin) have been found to result in S-phase arrest
in the cell cycle(31) and as such is a potent mediator of
apoptosis. With this in mind, both MG132 and valinomycin
were used to illustrate apoptotic effects on Calu-3 cells at
different levels of potency. On analysis of the fused images
of the negative ( b F4Fig. 4A) and positive (Fig. 4B and C)
control cell populations, a noticeable difference in appear-
ance was evident. Characteristics immediately noticeable in
toxic controls included total cell number decreases as well
as cytochrome c release and PMP increases in valinomycin-
treated samples (Fig. 4B and C).
In order to analyze the level of cytotoxicity elicited by
SC12CDClickpropylamine-siRNA nanocomplexes, nano-
complexes with MRs 10–100 were used to treat Calu-3 cells
and compared with untreated healthy cells 24 hr post trans-
fection. On examination of the change in cell count ( b F5Fig. 5A)
in toxic positive controls, it was found that there were very
significant levels of cell loss in both valinomycin (54.93%–
5.91%)– and MG132 (85.04%– 3.11%)–treated samples. In
contrast, for SC12CDClickpropylamine-siRNA–treated cells,
there was found to be a gradual decrease in cell number with
increasing MRs, up to 37%– 15.6% of total at MR= 100.
However, there were no statistically significant decreases
observed in cell populations at any MR examined.
Further examination of nuclear morphology characteristics
for nuclear area (Fig. 5B) in positive controls demonstrated
significant increases in valinomycin (19.11%– 5.21%)– and
MG132 (26.37%– 1.70%)–treated samples. Cells treated
with SC12CDClickpropylamine-siRNA–treated nanocom-
plexes did not demonstrate any statistically significant chan-
ges in nuclear area. Nuclear intensity analysis (Fig. 5C) of all
samples did not yield any significant changes compared with
untreated controls, with nuclear intensity actually decreasing
in CD-treated samples. However, an increase was seen in
FIG. 4. 10· image of gray-
scale images of each toxic-
ity parameter analyzed using
the Cellomics Multiparameter
Cytotoxicity kit for Calu-3
cells (A) untreated and (B)
4Cc
treated with 120lM valino-
mycin and (C) 40lMMG132.
Fused images were obtained
from analysis consisting of
Hoechst nuclear stain (blue),
PMP dye (green), and second-
ary antibody staining for cyto-
chrome c (Cyt C) (red).
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nuclear intensity in valinomycin-treated samples (as has
previously been reported(13)), but this could not be deemed
statistically significant in these experiments.
On analysis of the remaining cell death–associated char-
acteristics, SC12CDClickpropylamine nanocomplexes were
again found to be well tolerated and caused little change from
untreated cells. Specifically, for both MMP (Fig. 5D) and
cytochrome c release (Fig. 5E), there were again no statisti-
cally significant changes observed for CD-siRNA–treated
cells when compared with untreated cells. In contrast, the
positive controls for these parameters were found to exhibit
significant changes in MMP with increases of 17.95%–
6.33% and 11.74%– 5.13% observed for valinomycin and
MG132, respectively. Analysis of cytochrome c release in
toxic positive controls revealed conflicting results. Cyto-
chrome c release in valinoymcin-treated cells was found
to greatly increase (173.96%– 54.1%), whereas MG132 ex-
hibited a significant decrease in cytochrome c levels
(25.41%– 0.98%). This is mostly likely due to the difference
in potency of the two positive controls. With MG132 being
the more toxic of the two, it is likely that the cytochrome c
release had reached its maximum level earlier in the incu-
bation phase and had been released into the culture media and
lost following cell membrane breakdown.
The final parameter analyzed for evidence of cytotoxicity
was PMP whereby an increase in PMP would indicate a
reduction in the structural integrity of the cell membrane
associated with apoptosis. In a similar manner to cyto-
chrome c release, positive controls exhibited different be-
havior in their PMP values. Valinoymcin-treated samples
demonstrated increases in PMP of 113.17% – 35.5%,
whereas the more potent MG132 demonstrated a smaller
increase of 35.77%– 15.9% but was not deemed significant.
On analysis of SC12CDClickpropylamine-siRNA nano-
complex–treated cells, it was observed that the overall levels
of PMP rose with increasing MRs (Fig. 5F). However, these
increases did not reach statistical significance, with the ex-
ception of the highest MR= 100.
SC12CDClickpropylamine-siRNA nanocomplex
droplet size analysis
To establish the potential effect of SC12CDClickpropy-
lamine-siRNA nanocomplex formulations on droplets
FIG. 5. Quantitative multi-





Calu-3 cells measured at 24 hr
post administration. (A) Cell
count; (B) nuclear area; (C)
nuclear intensity; (D) MMP;
(E) cytochrome c (Cyt C)
release; and (F) PMP (sig-
nificance versus healthy
cells, one-way ANOVA,
n= 3, means–SEM, *p<0.05,
**p<0.01, ***p<0.001).
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emitted from the Aeroneb Pro nebulizer, a range of SC12CD
Clickpropylamine-siRNA nanocomplexes were formulated
at the most likely working MRs and assessed for changes in
VMD and % FPF compared with a 0.9% w/v saline solution
and unencapsulated siRNA (T3c Table 3).
On examination of the VMD and % FPF of each siRNA
nanocomplex system, it was found that there were no sig-
nificant changes when compared with saline and naked
siRNA controls. The VMD of siRNA nanocomplex solu-
tions remained around 4 lm in all cases, which is within the
required size range for successful delivery to the deep
lung.(32) In addition, the % FPF of each nebulized siRNA
nanocomplex sample remained at approximately 60% for all
samples. On analysis of the output rates associated with
each SC12CDClickpropylamine-siRNA nanocomplex, there
was no clear-cut trend apparent. Overall, output rates re-
mained roughly in line with saline and naked siRNA sam-
ples; however, there was a slight but nonsignificant decrease
in output efficiency apparent with increasing MRs in
SC12CDClickpropylamine samples.
SC12CDClickpropylamine-siRNA nanocomplex–
mediated luciferase knockdown in Calu-3 cells
SC12CDClickpropylamine-siRNA nanocomplexes were
formulated with 100 nM anti-luciferase siRNA in order to
assess their ability to knockdown luciferase expression in
pretransfected, luciferase-expressing Calu-3 cells. Samples
were incubated for 24 hr and then compared with the
transfection ability of the commercially available transfec-
tion reagent RNAiFect.
In the case of Calu-3 cells transfected with SC12CD
Clickpropylamine-siRNA nanocomplexes, it was found that
the optimal MR for transfection was at MR= 20. At this MR,
gene knockdown was found to be as high as 40% (F6c Fig. 6)
with significant levels of knockdown noted in individual
studies. Following this knockdown, efficiency appeared to
decrease with increasing MRs. When this was compared with
the percentage knockdown observed using RNAiFect, it was
found that the MR= 20 SC12CDClickpropylamine-siRNA
nanocomplexes exhibited slightly higher levels of knock-
down, though not statistically significant.
Postnebulization SC12CDClickpropylamine-siRNA
nanocomplex–mediated luciferase knockdown in Calu-
3 cells
The ability of the SC12CDClickpropylamine-siRNA na-
nocomplexes to retain functionality post nebulization was
also assessed using a luciferase knockdown assay ( b F7Fig. 7).
Postnebulization SC12CDClickpropylamine-siRNA nano-
complexes did not exhibit any significant changes in
knockdown ability in comparison with unnebulized samples.
As found previously in the siRNA nanocomplex HCA up-
take studies and luciferase knockdown studies, at 24 hr post
transfection, SC12CDClickpropylamine-siRNA nanocom-
plexes at MR = 20 remained the optimal formulation for
transfection before and after nebulization.
Discussion
Of key importance in the molecular kinetics of siRNA
nanocomplexes is analysis of their size and zeta potential.
Analysis of SC12CDClickpropylamine-siRNA nanocom-
plexes in this current study and previous studies has shown
that they are capable of forming compact nanocomplexes
between 125 and 200 nm in size and are highly cationic in
nature using dH2O.
(16,17,33,34) In addition, previous gel
Table 3. SC12CDClickpropylamine-siRNA
Nanocomplex Droplet Sizes Generated
and Fine Particle Fraction (FPF)










4.26 (– 0.02) 58.86 ( – 0.46) 0.41 ( – 0.00)
siRNA 4.27 (– 0.02) 58.78 ( – 0.38) 0.41 ( – 0.01)
CD MR= 10 4.23 (– 0.04) 59.45 ( – 0.71) 0.39 ( – 0.01)
CD MR= 20 4.17 (– 0.06) 60.31 ( – 0.96) 0.38 ( – 0.01)
CD MR= 30 4.13 (– 0.10) 60.98 ( – 1.58) 0.37 ( – 0.02)
FIG. 6. Percentage of SC12CDClickpropylamine-siRNA
nanocomplex–mediated luciferase knockdown in Calu-3
cells versus commercial RNAiFect control vector (knock-
down normalized versus nontargeting controls, one-way
ANOVA, n = 3, means – SEM).
FIG. 7. Postnebulization luciferase knockdown efficiency
of novel SC12CDClickpropylamine-siRNAnanocomplexes in
undifferentiated Calu-3 cells [significance versus unnebulized
samples, knockdown (KD) normalized versus nontargeting
controls, two-way ANOVA, n= 3, means–SEM].
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electrophoresis analysis by our group has also demonstrated
that SC12CDClickpropylamine nanocomplexes efficiently
encapsulate siRNA at MR> 10.(17) In contrast, this study
found that formulation of siRNA nanocomplexes in PBS
resulted in marked increases in particle size. This phenom-
enon has been previously reported for siRNA nanoparticles
and did not correlate to a loss in transfection efficiency.(35)
Due to the polydisperse nature of these particles and their
ability to elicit knockdown without toxicity, it is possible
that they are forming ‘‘nano-agglomerates’’ that may dis-
sociate into nano-sized particles on contact with the cell
membrane. This in itself has been investigated as a means of
deliverying nano-sized particles to the lung in an inhalable
format.(36) Similar results in our group have previously found
that whereas SC12CDClickpropylamine nanocomplexes in-
crease in size following 24hr of incubation in fetal bovine
serum (FBS),AU3c particle size remains less than 250 nm up to 4 hr
of incubation, which still allows for rapid internalization into
cells.(37) This was also observed in this study using cell
culture media containing FBS and high-throughput screening
assays for cell uptake of SC12CDClickpropylamine nano-
complexes over a 24-hr period.
The use of high-throughput screening methods offers a
means of gaining a detailed understanding of particle-cell
trafficking and drug-induced cytotoxicity. This has previ-
ously been successfully applied by our group to monitor
drug delivery and excipient toxicity in a range of different
cells types including colonic and lung epithelial cells as
well as in alveolar macrophages.(13,38,39) Through HCA
screening, the uptake of SC12CDClickpropylamine-siRNA
nanocomplexes into Calu-3 cells was assessed at 2, 4, and
24 hr. Significantly enhanced levels of siRNA nanocom-
plex uptake were recorded compared with commercial
controls as rapidly as 2 hr post treatment, which were most
likely due to its highly cationic nature. It has been suggested
that cationic nanocomplexes similar to SC12CDClickpro-
pylamine nanocomplexes utilize multiple endocytic path-
ways in airway epithelial cells including clathrin and
caveolae-mediated endocytosis.(40,41) This would allow for
a rapid influx of SC12CDClickpropylamine-siRNA nano-
complexes into cells in a relatively short amount of time fol-
lowing administration of SC12CDClickpropylamine-siRNA
nanocomplexes.
In addition, it is worth noting that at 24 hr post treatment,
the greatest levels of uptake did not correspond to increases
in MR. Whereas at earlier time points, rates of SC12CD
Clickpropylamine-siRNA nanocomplex uptake were broadly
in line with increasing MR, at 24 hr post treatment two-way
ANOVA analysis of uptake rates revealed that MR= 20
SC12CDClickpropylamine-siRNA nanocomplexes achieved
significantly higher levels of cell uptake compared with all
other SC12CDClickpropylamine-siRNA formulations. In
combination with this, it was also found that whereas levels
of internalized siRNA nanocomplexes remained relatively
static in MRs 30–100, the amount of internalized SC12CD
Clickpropylamine-siRNA nanocomplexes at MR= 10 and 20
changed significantly over a 24-hr time period. In attempt-
ing to explain this phenomenon, it was noticed that physi-
cochemical properties (i.e., size and zeta potential) of the
various MR formulations were similar and not likely to ex-
plain this difference. However, multiparameter cytotoxicity
analysis had detected a proportional increase in PMP with
increasing MR of SC12CDClickpropylamine-siRNA nano-
complex used. This may indicate that the rapid uptake of high
levels of high-MR SC12CDClickpropylamine-siRNA nano-
complexes was being facilitated by their own increasingly
cytotoxic nature. In contrast, the high levels of uptake
observed over the full 24-hr time period in the MR= 10 and
20 SC12CDClickpropylamine-siRNA nanocomplexes were
more likely due to normal cell endocytosis.
Using high-throughput multiparameter analysis of toxicity,
it was found that the SC12CDClickpropylamine nanocom-
plexes were well tolerated at all MRs with no significant
changes in all parameters in comparison with untreated
controls (with the exception of PMP). This is in line with
earlier toxicity studies of these nanocomplexes in Caco-2
colonic epithelial cells and N41 neuronal cell lines as well as
primary rat embryonic neuronal cells.(16,17) It should be no-
ted, however, that trends toward toxicity were noted as MR
increased with decreases in cell population of up to
34%– 12% and increases in cytochrome c, MMP, and PMP
all evident as MR increased, with significant increases in
PMP at MR= 100. Although it is expected for MMP to drop
in apoptotic cells, it has previously been found that some
epithelial cells will exhibit an increase in MMP prior to a loss
of MMP if the dose is increased.(13,38) This would indicate a
dose-dependent relationship with regard to SC12CDClick-
propylamine-siRNA nanocomplex–mediated toxicity, which
has also been seen in unmodified CD delivery to Calu-3
cells.(42) Finally, this high level of cell viability was found to
be in contrast to previous studies indicating the cytotoxic
nature of preexisting transfection agents such as PEI and
RNAiFect-siRNA nanocomplexes.(13,43) With specific regard
to RNAiFect, Arima et al. found that although well tolerated
at MR£ 6, RNAiFect-siRNA nanocomplexes resulted in de-
creases in cell viability of up to 60% when MRs increased up
to MR= 10.(43)
To our knowledge, this is the first investigation into the
siRNA transfection efficiency of a modified cationic CD of
this nature in airway epithelial cells. Calu-3 cells were se-
lected as they are a well established cell line that is often
used in early lung deposition studies.(44) Overall, it was
found that SC12CDClickpropylamine nanocomplexes me-
diated levels of luciferase knockdown in Calu-3 cells that
were comparable to knockdown levels in the RNAiFect
commercial control. This optimal level of knockdown at
MR= 20 was also successfully predicted using HCA anal-
ysis, which indicated optimal siRNA uptake at MR= 20. An
additional contrast was noted between the significantly
higher levels of uptake of SC12CDClickpropylamine-siR-
NA nanocomplexes compared with RNAiFect-siRNA na-
nocomplexes and their comparable levels of luciferase
knockdown. This was mostly likely due to a previously
described phenomenon whereby it is possible that the RNAi
uptake and trafficking machinery can become saturated in
the presence of large amounts of short-chain RNAs such as
siRNA or miRNA.(45–47) This would imply that the highly
efficient means by which SC12CDClickpropylamine-siRNA
nanocomplexes are internalized could be managed in the
future by a reduced dose, thereby reducing the potential for
adverse reactions even further.
Furthermore, levels of gene knockdown in Calu-3 cells
were similar to those seen using other cationic polysac-
charides such as chitosan in more easily transfected cells
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lines such as HeLa and HEK where knockdown levels of
approximately 50% were reported.(48,49) Finally, knock-
down levels observed in this study were also comparable to
levels of the gold standard, branched PEI (25 kDa) in vitro
siRNA knockdown, which ranged from 30% to 60% de-
pending on the cell type used,(13,50) with none of the PEI-
associated toxicity issues. The variations observed in
knockdown efficiency using this particular SC12CDClick-
propylamine are likely due to the different microenviron-
ments within each cell type and target gene examined. A
variety of knockdown levels have also been reported in
other studies using several different modified CD constructs,
ranging from*40% to 80%(33,51–53) using both in vitro and
in vivo models.
In this study, an additional step was under taken to examine
the behavior of these SC12CDClickpropylamine nanocom-
plexes following nebulization. Expelled droplets containing
SC12CDClickpropylamine-siRNA nanocomplexes were
found to be of appropriate diameter for deep lung delivery,
with the % FPF indicating that 50–60% of expelled particles
were < 5lm. Overall, these results were in agreement with
previous studies involving nebulized CDs whereby nebuliza-
tion of CD-drug combinations resulted in no loss in output
performance and an increase in emitted drug in cases.(18,54)
Coupled with this, postnebulization transfection ability ap-
peared to be unaltered using the Aeroneb Pro vibrating mesh
nebulizer. The use of a nebulizer in early screening studies for
siRNA delivery is also of high importance, as this is a clini-
cally relevant mode of siRNA delivery as opposed to solely
investigatory modes such as intratracheal microsprayers and
whole-bolus nasal delivery. Investigations using clinically
relevant siRNA delivery models remain in the minority with
only one previous study undertaking similar experiments.(35) It
is encouraging to note, however, that this study also reported
high levels of siRNA stability using the Aeroneb Pro system.
With this inmind, this new generation of nebulizer technology,
coupled with the appropriate siRNA delivery vector appears to
have great potential in maintaining siRNA stability. This will
allow for successful future scale-up and testing in more com-
plex in vitro and in vivomodels for a more comprehensive and
in-depth examination of therapeutic potential.
Conclusions
Novel gene and siRNA delivery vector designs and inno-
vations based on existing molecules are constantly being de-
veloped, and the need for rapid and accurate evaluation is of
paramount importance if they are to reach their clinical and
commercial potential. Evaluations must, of course, be de-
signed with specific regard to the particular environment
within the body to which the siRNA is to be directed and any
interface with devices that are required. With this in mind, the
high-throughput methods that we have successfully optimized
in our previous studies were harnessed to examine a com-
pletely novel vector for delivering siRNA to airway epithelial
cells. This gene delivery vector, a modified cationic CD, was
assessed over a range of parameters in order to rapidly and
comprehensively screen the various formulations of CD-siRNA
nanocomplex for transfection to airway epithelial cells.
These studies revealed that SC12CDClickpropylamine
was capable of forming highly cationic nanocomplexes with
siRNA, which traversed the cell membrane at high levels,
were well tolerated by epithelial cells, and mediated levels
of knockdown at MR= 20 that were comparable to com-
mercial controls. Aerosol delivery is a device-dependent
approach, and by using Aeroneb vibrating mesh nebulizers,
the transfection ability of the SC12CDClickpropylamine-
siRNA nanocomplexes was undiminished following nebu-
lization. Following this study, it was found that SC12CD
Clickpropylamine-siRNA nanocomplexes can be effectively
nebulized for pulmonary delivery of siRNA using Aeroneb
technology to mediate knockdown in epithelial cells. Herein
an integrated nanomedicine-device platform was developed
for potential application in preclinical and clinical studies of
inhaled siRNA therapeutics.
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